Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Pitfalls of using FDG-PET for the diagnosis of bone metastases identified
January 26th, 2006
The pitfalls of using 2-[F-18]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for the diagnosis of bone metastases were highlighted. "The purpose of this study was to investigate the pitfalls of using FDG-PET for the evaluation of osteoblastic bone metastases in patients with breast cancer by comparing it with Tc-99m-hydroxymethylene diphosphonate bone scintigraphy," scientists writing in the European Journal of Nuclear Medicine and Molecular Imaging reported. "Among the 89 breast cancer patients (mean age 59±15 years) who had undergone both FDG-PET and bone scintigraphy within 1 month between September 2003 and...
Source: Women's Health Weekly (2006-01-26)
|
